Milestone Pharmaceuticals (NASDAQ:MIST) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $3.00 price target on the stock.

A number of other research analysts also recently commented on the stock. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Finally, Wells Fargo & Company lowered their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Milestone Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $6.40.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $1.05 on Thursday. The stock has a market cap of $131.35 million, a PE ratio of -1.53 and a beta of 0.98. The business has a fifty day simple moving average of $1.21 and a 200-day simple moving average of $1.49. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25. Milestone Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $0.82 million. On average, sell-side analysts anticipate that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Strategic Family Wealth Counselors L.L.C. acquired a new position in Milestone Pharmaceuticals in the fourth quarter worth approximately $25,000. Eaton Financial Holdings Company LLC acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at approximately $26,000. Welch & Forbes LLC bought a new stake in Milestone Pharmaceuticals in the first quarter worth approximately $30,000. Bank of America Corp DE grew its position in Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth $42,000. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.